BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29538414)

  • 1. Biomolecular study of human thymidylate synthase conformer-selective inhibitors: New chemotherapeutic approach.
    El-Mesallamy HO; El Magdoub HM; Chapman JM; Hamdy NM; Schaalan MF; Hammad LN; Berger SH
    PLoS One; 2018; 13(3):e0193810. PubMed ID: 29538414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analyses of human thymidylate synthase reveal a site that may control conformational switching between active and inactive states.
    Chen D; Jansson A; Sim D; Larsson A; Nordlund P
    J Biol Chem; 2017 Aug; 292(32):13449-13458. PubMed ID: 28634233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human thymidylate synthase with loop 181-197 stabilized in an inactive conformation: ligand interactions, phosphorylation, and inhibition profiles.
    Luo B; Repalli J; Yousef AM; Johnson SR; Lebioda L; Berger SH
    Protein Sci; 2011 Jan; 20(1):87-94. PubMed ID: 21064161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors.
    Lovelace LL; Gibson LM; Lebioda L
    Biochemistry; 2007 Mar; 46(10):2823-30. PubMed ID: 17297914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP.
    Almog R; Waddling CA; Maley F; Maley GF; Van Roey P
    Protein Sci; 2001 May; 10(5):988-96. PubMed ID: 11316879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors.
    Pozzi C; Ferrari S; Luciani R; Costi MP; Mangani S
    Molecules; 2019 Apr; 24(7):. PubMed ID: 30959951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.
    Marverti G; Gozzi G; Maretti E; Lauriola A; Severi L; Sacchetti F; Losi L; Pacifico S; Ferrari S; Ponterini G; Leo E; Costi MP; D'Arca D
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells.
    Shaw D; Berger FG; Spencer HT
    Hum Gene Ther; 2001 Jan; 12(1):51-9. PubMed ID: 11177542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
    Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
    Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth.
    Pacifico S; Santucci M; Luciani R; Saxena P; Linciano P; Ponterini G; Lauriola A; D'Arca D; Marverti G; Guerrini R; Costi MP
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31561530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-resistant variants of Escherichia coli thymidylate synthase: effects of substitutions at Pro-254.
    Fantz C; Shaw D; Jennings W; Forsthoefel A; Kitchens M; Phan J; Minor W; Lebioda L; Berger FG; Spencer HT
    Mol Pharmacol; 2000 Feb; 57(2):359-66. PubMed ID: 10648646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ligand binding and conformational switching on intracellular stability of human thymidylate synthase.
    Berger SH; Berger FG; Lebioda L
    Biochim Biophys Acta; 2004 Jan; 1696(1):15-22. PubMed ID: 14726200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug.
    Phan J; Koli S; Minor W; Dunlap RB; Berger SH; Lebioda L
    Biochemistry; 2001 Feb; 40(7):1897-902. PubMed ID: 11329255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
    Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
    J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The R163K mutant of human thymidylate synthase is stabilized in an active conformation: structural asymmetry and reactivity of cysteine 195.
    Gibson LM; Lovelace LL; Lebioda L
    Biochemistry; 2008 Apr; 47(16):4636-43. PubMed ID: 18370400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase inhibitors.
    Touroutoglou N; Pazdur R
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase.
    Salo-Ahen OM; Tochowicz A; Pozzi C; Cardinale D; Ferrari S; Boum Y; Mangani S; Stroud RM; Saxena P; Myllykallio H; Costi MP; Ponterini G; Wade RC
    J Med Chem; 2015 Apr; 58(8):3572-81. PubMed ID: 25798950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
    Chu E; Callender MA; Farrell MP; Schmitz JC
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S80-9. PubMed ID: 12819937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents.
    El-Naggar AM; Abou-El-Regal MM; El-Metwally SA; Sherbiny FF; Eissa IH
    Mol Divers; 2017 Nov; 21(4):967-983. PubMed ID: 28815411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity.
    Li XY; Zhang TJ; Kamara MO; Lu GQ; Xu HL; Wang DP; Meng FH
    Cell Death Dis; 2019 Jul; 10(7):532. PubMed ID: 31296849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.